Alerje, founded with the mission to improve the quality of life for individuals affected by food allergies, offers a comprehensive digital health platform. The company’s core products include an app that allows users to create and share food allergy profiles, filter recipes, and scan grocery items for allergens. Additionally, Alerje has developed an innovative epinephrine auto-injector integrated into a smartphone case, enhancing patient adherence and providing timely alerts. Their market focus is on the over 220 million people worldwide who suffer from food allergies.
Notable affiliated individuals and investors include experts in digital health and emergency medicine, although specific names are not disclosed. Key achievements of Alerje include the successful development and deployment of their integrated epinephrine auto-injector and app, which have significantly impacted the daily management of food allergies. The overall impact of Alerje is seen in its ability to provide practical tools that empower users to take control of their food allergies, thereby improving their quality of life.
